NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP 50 Pharmas » Novartis  1    
found files: 18
Novartis »11/02/2007 [Company watch]
Novartis to focus on Hepatitus drugs in China

Novartis will launch a product for hepatitus B this year as it is China\\\'s prevalent disease with approx 20 million affected. CEO Vasella says they have been growing by 20% on average over the last 5 years and gained considerable market share....   more»

Novartis »23/04/2007 [Company watch]
Novartis with dynamic growth in the 2007 first quarter

Strong 2007 first quarter performance as Group net sales advance 18% (+15% in local currencies) to USD 9.8 billion on excellent performances from all divisions Group continuing operations operating income up 18%, net income up 17%...   more»

Novartis »07/08/2007 [Company watch]
Novartis delivers strong performance in first half of 2007 (H1 - Report)

...   more»

Novartis »08/08/2007 [Industry news]
MNCs may go to China for R&D

NEW DELHI: Multinational drug makers would prefer China for investments in pharmaceutical research so long as India keeps the bar for patenting a drug so high, warns drug major Novartis on Monday after the Madras High Court turned down the company\'s challenge to the country’s patent law....   more»

Novartis »25/08/2007 [Company watch]
Novartis to move Indian R&D operations to China

Swiss pharmaceutical giant Novartis AG will move hundreds of millions of dollars in planned investments from India to China over the next few years in response to an Indian court ruling that weakens intellectual property rights on new medicines, according to a report on the Financial Times\' Web site....   more»

Novartis »04/12/2007 [Company watch]
Beijing Med-Pharm Announces Exclusive Agreement to Market Enablex® in China

Beijing Med-Pharm Corporation (NASDAQ:BJGP) ("Beijing Med-Pharm" or the "Company"), one of China’s leading pharmaceutical companies, and Shanghai Novartis Trading Limited, a wholly owned subsidiary of Novartis AG (NYSE: NVS), one of the top five pharmaceutical companies in the world, today announced an exclusive agreement to register, market and distribute Enablex® (Darifenacin) in the People's Republic of China....   more»

Novartis »28/02/2008 [Company watch]
Novartis annual results reports significant China growth in 2007

Novartis announced 2007 financial results on February 28. In 2007, sales for Novartis China rose by 25% to RMB 2.58 billion. Beijing Norvatis Pharmaceutical's sales totaled RMB 2.0 billion, 27% year over year growth. Global results T/O $ 38,100 millions Net Profit $ 6.500millions R & D Spend $6,400 millions According to the report, sales of the anti hypertension drugs Diovan and Lotensin both increased substantially; sales of Lotensin alone exceeded RMB 400 million. Four other products, Voltaren, Glivec, Sandimmun, and Miacalive, also achieved sales of more than RMB 100 million in 2007. Sales of Novartis vaccines were greater than RMB 50 million. The company predicts that it will see growth of more than 20% in 2008. Novartis also announced that it has begun construction of a new R&D center in Shanghai and expects to have Suzhou facility production ready in 2008....   more»

Novartis »25/06/2008 [Company watch]
SFDA approves Novartis flu vaccine for elderly

The State Food and Drug Administration (SFDA) announced June 25 that it has approved the first influenza vaccine for the elderly in China. The vaccine, Fluad®, is an MF59-adjuvanted vaccine made by Novartis. According to the World Health Organization (WHO), many influenza strains originate in China; however, less than 5% of the elderly in China receive immunization. In some developed countries, nearly 60% of the elderly population receives influenza vaccinations....   more»

Novartis »26/02/2009 [Company watch]
Novartis China sales grow 29%, more product launches in the works

At Novartis China\'s 2009 press conference held February 25, Jeffrey Li, president of Novartis China, said that total sales in 2008 exceeded RMB 3.3 billion with 29% year-over-year growth. From 2004 to 2008, the compound growth rate of its investment in China was 76%, reaching a total of RMB 2.2 billion....   more»

Novartis »06/03/2009 [Company watch]
Novartis reported that 2008 revenues in China were up 29%

Novartis reported that 2008 revenues in China were up 29% to 3.3 billion RMB ($428 million). The company expects its China sales to rise another 30% in 2009....   more»

Novartis »04/05/2009 [Company watch]
Novartis and China Medical Doctor Association team up for hypertension survey

The Chinese Medical Doctor\'s Association, the Chinese Hypertension League, and Novartis have jointly launched a research study on the current status of treatments for hypertension...   more»

»17/07/2009 [Industry news]
Novartis AG to Offer Management BiMBA in China

In Beijing, Novartis has established a Sino-European Novartis University of China...   more»

»04/11/2009 [Company watch]
Novartis buys China vaccine stake for $125 mln

Swiss drugmaker Novartis is buying an 85 percent stake in privately owned Chinese vaccines company Zhejiang Tianyuan...   more»

»03/11/2009 [Company watch]
Novartis International AG to Invest $1 Billion in China

Novartis announced today a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis\' long term commitment to China\'s further economic development, health reform and improving the health care of the Chinese people....   more»

Novartis »16/11/2009
Novartis Says Weak IP Protection Makes India R&D Impossible

Novartis once again said that India is not a place to do R&D because its IP laws are not strong enough to protect discoveries. In 2006, Novartis made a commitment to build a $125 million R&D facility in Hyderabad....   more»

»13/11/2009 [Company watch]
Novartis to acquire majority stake in HTDS Chinese subsidiary

Hard To Treat Diseases has announced that Novartis is acquiring an 85 percent stake in HTDS\' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical, for $125 million....   more»

Novartis »16/12/2009 [Company watch]
Novartis Increases China Commitment: Opens Suzhou Plant, Technical R&D Centre

In November, Novartis held the official opening of Suzhou Novartis Pharma Technology Co., the company’s new $250 million centre devoted to technical R&D as well as manufacturing of APIs and intermediates....   more»

»17/03/2010 [Company watch]
Novartis China: Spectacular Climb in 2009

Novartis AG , the Swiss multinational pharma, said revenues in China grew 36% last year...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.